ELVN-002
Showing 1 - 25 of 314
HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,
Not yet recruiting
- HER2 Mutant Non-small Cell Lung Cancer
- +3 more
- ELVN-002
- +2 more
- (no location specified)
Dec 6, 2022
Hair Diseases, Alopecia, Hair Loss Trial in Manaus (DA-OTC-002)
Completed
- Hair Diseases
- +2 more
- DA-OTC-002
-
Manaus, BrazilHospital Oscar Nicolau
Oct 20, 2023
Non-muscle Invasive Bladder Cancer Trial (TARA-002)
Not yet recruiting
- Non-muscle Invasive Bladder Cancer
- TARA-002
- (no location specified)
Jul 14, 2023
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- +14 more
- ELI-002 7P
- (no location specified)
Feb 3, 2023
Vaccine-Preventable Diseases, Hepatitis B Trial in Seongnam-si (CVI-HBV-002)
Completed
- Vaccine-Preventable Diseases
- Hepatitis B
- CVI-HBV-002
-
Seongnam-si, Gyeonggi-do, Korea, Republic ofCHA University Bundang Medical Center
Nov 19, 2023
Refractory Focal Epilepsy Trial in Beijing (iPSC-Exos)
Recruiting
- Refractory Focal Epilepsy
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 5, 2023
Hidradenitis Suppurativa, Atopic Dermatitis, Healthy Volunteer Trial (LT-002-158/Placebo oral tablet(s))
Not yet recruiting
- Hidradenitis Suppurativa
- +2 more
- LT-002-158/Placebo oral tablet(s)
- (no location specified)
Oct 9, 2023
Lymphatic Malformation Trial (TARA-002)
Not yet recruiting
- Lymphatic Malformation
- TARA-002
- (no location specified)
May 22, 2023
Myopia Trial in Worldwide (NVK-002 Concentration 1, NVK-002 Concentration 2, Placebo)
Active, not recruiting
- Myopia
- NVK-002 Concentration 1
- +2 more
-
Tucson, Arizona
- +25 more
Jan 3, 2023
Autism Spectrum Disorder Trial in Staten Island (ML-004 (IR)/(ER) tablet)
Recruiting
- Autism Spectrum Disorder
- ML-004 (IR)/(ER) tablet
-
Staten Island, New YorkRichmond Behavioral Associates
Jun 1, 2023
Hemophilia B Trial in Russian Federation (ANB-002, dose 1, ANB-002, dose 2)
Recruiting
- Hemophilia B
- ANB-002, dose 1
- ANB-002, dose 2
-
Chelyabinsk, Russian Federation
- +14 more
Nov 4, 2023
Prostate Cancer Trial in United States (drug, device, procedure)
Recruiting
- Prostate Cancer
- Administration of IS-002
- +2 more
-
San Francisco, California
- +3 more
Jul 7, 2023
T-GENVIH-003 LTFU (Long Term Follow Up) Study
Not yet recruiting
- Hernia
- +3 more
- Integra® Gentrix® Surgical Matrix
-
Fort Myers, FloridaSurgical Healing Arts
Sep 12, 2023
Malaria Trial in Worldwide (Blood sampling, Assessment of body temperature)
Recruiting
- Malaria
- Malaria Vaccines
- Blood sampling
- Assessment of body temperature
-
Nouna, Burkina Faso
- +11 more
Sep 8, 2022
Myopia, Myopia Progression, Juvenile Myopia Trial in United States (Novel spectacle lens design, Spectacle lenses)
Not yet recruiting
- Myopia
- +2 more
- Novel spectacle lens design
- Spectacle lenses
-
Longwood, Florida
- +5 more
Dec 6, 2022
Dry Eye Disease Trial in Andover (glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%)
Enrolling by invitation
- Dry Eye Disease
- glycerin 0.7%/PEG 400 0.3%
- polyethylene glycol 400 0.4%/propylene glycol 0.3%
-
Andover, MassachusettsAndover Research Eye Institute
Dec 20, 2022
Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, New York (PTR-01)
Completed
- Recessive Dystrophic Epidermolysis Bullosa
-
Redwood City, California
- +1 more
Nov 17, 2022
Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)
Recruiting
- Cancer
- +4 more
- INKmune
-
Athens, Attiki, Greece
- +2 more
Jul 3, 2023
Advanced Solid Tumors With MAPK Pathway Mutations Trial in Nedlands (D3S-002)
Not yet recruiting
- Advanced Solid Tumors With MAPK Pathway Mutations
-
Nedlands, Western Australia, AustraliaD3 Bio Investigative Site
May 24, 2023